Paras Biopharmaceuticals Finland Oy provides investors with a great opportunity for an exciting and rewarding partnership
Paras Biopharmaceuticals Finland Oy offers investors a great opportunity for an exciting and rewarding partnership in addition to the opportunity to participate in a unique business opportunity.
The management of Paras Biopharmaceuticals Finland Oy brings together key skills, a technology platform and intellectual capital for four soon to be off-patent blockbuster biosimilar drugs.
Anti-diabetic products are currently a “high demand high growth area” which presents an immediate opportunity especially when a $26 billion market is expected to be open due to off-patent products by 2015.
Paras Biopharmaceuticals Finland Oy's strategy is to create a healthy pipeline of products based on its technology platform and use this foundation for further offerings of therapeutic mAbs fragments that will come out of patent between 2016-2020 and beyond.
Paras Biopharmaceuticals Finland Oy provides an excellent opportunity for value creation and is currently in active discussions for technology out-licensing in Asia, GCC countries, Africa and CIS countries, Europe and the USA.
This website uses cookies; by continuing to use this page, you consent to their use. I Understand About Cookies.